Tumour‐derived exosomes as antigen delivery carriers in dendritic cell‐based immunotherapy for malignant mesothelioma

Abstract

In this study, we showed that DC immunotherapy loaded with tumour exosomes derived from non-immunogenic tumours improved survival of tumour bearing mice.